A simplified schedule of high-dose chemotherapy consisting of cyclophosphamide (60 mg/kg/day for 2 days), etoposide (15 mg/kg/day for 2 days) and carboplatine (400 mg/m 2 /day for 2 days), together with autologous non-cryopreserved peripheral blood stem cells was used for treatment of relapsed (29 patients) and refractory (three patients) patients with non-Hodgkin's lymphoma (NHL). The use of such granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) after high-dose myeloablative therapy resulted in a rapid, complete and sustained hematopoietic recovery. The median time to achieve an absolute neutrophil count greater than 0.5 Â 10 9 /l was 12 days (range 8-17 days). The median time to self-sustained platelet count greater than 20 Â 10 9 /l was 14 days (range 7-19 days). Fifteen of the 32 patients (49%) were alive and disease free at a median follow-up of 18 months (range 10-96 months) for all surviving patients. The estimated 2-year overall survival (OS) and disease free survival (DFS) for all patients were 50 and 43%, respectively. Twelve patients died of relapse or progressive disease, two patients died of infection and one patient died of cardiac cause. The median time to relapse was 12 months (5-27) from PBSC infusion. High-dose chemotherapy with short-duration chemotherapy and non-cryopreserved bone marrow (BM) is an effective and safe treatment modality for patients with relapsed or resistant NHL.
Introduction
Although approximately 40% of the patients with advanced intermediate-and high-grade non-Hodgkin's lymphoma (NHL) can be cured with conventional combination chemotherapy, the majority still die of their disease. Several prognostic variables have been identified in an attempt to identify a subset of patients with aggressive NHL who have a poor prognosis and are unlikely to be cured with conventional chemotherapy. 1 High-dose therapy followed by autologous stem cell transplantation has been shown to produce long-term disease-free survival (DFS) in selected patients with poor risk NHL. 2, 3 However, the conventional procedures for collection and freezing of peripheral blood stem cells (PBSCs) are time consuming and expensive 4 and methods to simplify bone marrow (BM) transplantation procedures are needed mainly in developing countries.
Hematopoietic stem cells appear to maintain viability for several days after collection if carefully stored refrigerated.
Patients were compared for the efficacy, safety and cost efficiency of BM transplant after either refrigeration or cryopreservation of the stem cells. No clinically meaningful variation in post transplant outcome between refrigerated storage and cryopreservation was found. Refrigeration storage requires no special equipment, is cheaper than and presents a safe and viable alternative to cryopreserved BM in reconstituting hematopoiesis following high-dose chemo-radiotherapy. 5, 6 Refrigerated storage was supplanted by cryopreservation as most transplant centers developed multiday conditioning regimens. Indeed, there is limited experience with autologous transplantation of non-cryopreserved hematopoietic stem cells. We herein present the results of 32 NHL patients preconditioned with cyclophosphamide, etoposide and carboplatine who received non-cryopreserved unmanipulated PBSC transplantation for their relapsed or refractory disease.
Patients and methods
Between 1996 and 2003, 32 patients with relapsed or refractory NHL underwent high-dose therapy and auto-logous peripheral stem cell transplantation at the BM transplant unit, Mansoura faculty of Medicine, Egypt. The diagnosis and histological subtype of NHL was based on biopsy results.
Study definitions and evaluation
Patients were defined as having induction failure if they had received induction chemotherapy with or without salvage therapy and were never documented to be in a complete remission (CR). A sensitive relapse was defined as at least a 50% reduction in the bi-dimensional measurements of the disease with the use of conventional salvage chemotherapy or radiotherapy. A resistant relapse was defined as less than 50% reduction in the size of the tumor with the use of conventional salvage chemotherapy or radiotherapy.
Patients were clinically restaged at the time of entry into the study. Restaging procedures were repeated at days þ 30 and þ 90 after transplant, or as clinically indicated. Follow-up tumor restaging was performed every 3-6 months for 2 years, then yearly unless recurrence was suspected. Patients who survived at least day þ 30 and had no evidence of tumor by clinical and radiological evaluation for at least 1 month were classified as having a CR. Patients who received transplants in CR without evidence of disease were considered to be in continuous CR after transplant. Partial remission (PR) was defined as a reduction of 50% or more of measurable disease for at least 1 month.
Patients selection
Patients were eligible for PBSCT if they had failed to achieve CR after first-line chemotherapy (induction failure) or if they had relapsed after standard chemotherapy regimen. Patients whose first relapse occurred more than 12 months after completion of induction chemotherapy were not candidates for transplant unless they had failed to respond to standard salvage chemotherapy or had relapse at extranodal sites. Additional eligibility criteria included age o60 years, Karnofsky performance status (KPS) X70, left ventricular ejection fraction 450%, forced expiratory volume in 1 s (FEV1) 450% and no major organ dysfunction unrelated to their underlying lymphoma.
The patient characteristics at the time of diagnosis are shown in Table 1 . The median age was 34 years (range 17-55 years). There were 20 male and 12 female patients. Twenty-two patients (68.7%) had stage IV disease and 13 (40.6%) had 'B' symptoms at the time of diagnosis. Ten (31.3%) had elevated lactase dehydrogenase levels and nine (28.1%) had extranodal involvement at diagnosis. Eighteen patients (56.3%) had diffuse large B-cell lymphoma, nine (28.1%) had anaplastic large-cell lymphoma and five (15.6%) had Burkitt's lymphoma. Bone marrow involvement was detected in five patients (15.6%).
Details of prior therapy are outlined in Table 2 . All patients were treated with induction chemotherapy for a minimum of three cycles or until they had achieved CR or minimal disease state. The median number of prior chemotherapy regimens was 4 (range [3] [4] [5] [6] [7] [8] . Three patients (9.4%) had received prior radiotherapy either at initial presentation or as salvage therapy for relapse. Conventional salvage chemotherapy was given to all relapsed patients (nineteen patients (59.4%) received DHAP and thirteen (40.6%) received ESHAP). Most patients received 2-3 cycles of salvage therapy to achieve maximal response before transplant.
The patient characteristics at the time of transplant are shown in Table 3 . Five patients (15.6%) received transplants in second CR. A total of 24 (75%) patients received transplants after second or subsequent relapse. The median duration of first CR to first relapse was 10 months (range 3-14 months). Nineteen of the relapsed patients (59.4%) Non-cryopreserved autologous PBSCT M Mabed and T Al-Kgodary had sensitive relapse. Three patients (9.4%) were transplanted after induction7salvage chemotherapy or chemoradiotherapy failure. The median KPS was 90% (range 80-100). Eight patients (25%) had extranodal diseases at the time of transplantation.
Mobilization of progenitor cells
Patients received single dose of cyclophosphamide (1.5 g/ m 2 ) followed after 5 days by 5 mg/kg/day recombinant human granulocyte colony-stimulating factor (rhG-CSF); rhG-CSF was continued until the end of leukapheresis.
Collection and preservation of PBSCs
After the administration of chemotherapy, patients had complete blood counts measured daily and began leukapheresis when the total white blood count recovered to 3 Â 10 9 /l, usually at the ninth to eleventh day from the start of mobilization. Leukapheresis was performed daily until the collection of greater than 2 Â 10 8 mononuclear cells/kg and greater than 3 Â 10 6 CD34 þ cells/kg patient weight. The final product was stored at 41C for a maximum of 72 h. Viability was assessed by Trypan blue dye exclusion test 24, 48 and 72 h after harvesting.
The conditioning regimen
The conditioning regimen for transplantation contained cyclophosphamide (60 mg/kg/day for 2 days), etoposide (15 mg/kg/day for 2 days) and carboplatine (400 mg/m 2 /day for 2 days). At 24 h after the end of chemotherapy, the noncryopreserved stem cells were re-infused.
Statistical analysis
Neutrophil recovery was defined as the first of 2 consecutive days of neutrophil counts 40.5 Â 10 9 /l. Platelet recovery was defined as the first of 7 consecutive days with platelet count 420 Â 10 9 /l unsupported by transfusion. Disease free survival was defined as the time from PBSC reinfusion to the time of disease progression or last followup. Overall survival (OS) was defined as the time from reinfusion of PBSC to death or date of last follow-up.
Survival distributions were assessed using Kaplan-Meier estimates. 7 
Results

Viability assessment
Trypan blue dye exclusion test showed 490% viability in all samples studied 24, 48 and 72 h after harvesting.
Hematopoietic recovery
Successful PBSC collection was achieved in all patients. The use of such G-CSF-mobilized PBSC after high-dose myeloablative therapy resulted in a rapid, complete and sustained hematopoietic recovery in all patients. The median time to achieve an absolute neutrophil count greater than 0.5 Â 10 9 /l was 12 days (range 8-17). The median time to self-sustained platelet count greater than 20 Â 10 9 /l was 14 days (range 7-19).
Assessment of response
All patients were assessable for response. No early deaths occurred. At 30 days, 22 patients (68%), including the five patients transplanted in CR, were in CR. Two patients (6.2%) achieved PR. Six patients (18.8%) had a stable disease and two patients (6.2%) did not respond. Without additional treatment, the 3 month restaging showed 26 patients (81.3%) in CR, one patient (3.1%) in PR, two patients (6.2%) with stable disease and three patients (9.4%) suffered disease progression.
Overall survival and disease free survival Fifteen of the 32 patients (49%) were alive and disease free at a median follow-up of 18 months (range 10-96 months) for all surviving patients. The estimated 2-year OS and DFS for all patients were 50 and 43%, respectively (Figure 1 ). Twelve patients died of relapse or progressive disease, two patients died of infection and one patient died from cardiac problems. The median OS time for all patients was 18 months (range 7-96 months). No evidence of graft failure was present by the time of death for any patient. The Non-cryopreserved autologous PBSCT M Mabed and T Al-Kgodary median time to relapse was 12 months (5-27) from PBSC infusion.
Discussion
The conventional procedures for collection and freezing of PBSCs are time consuming and expensive. Methods to simplify BM transplantation procedures are needed mainly in developing countries. Refrigerated storage for short-term preservation of BM is an alternative to cryopreservation.
In an in vitro analysis, stem cell population was concentrated and the nucleated cell recovery, viability and colony-forming potential were compared following refrigerated storage of whole BM and buffy coat to cryopreserved BM stored for the same interval. Whereas the nucleated cell recovery for cryopreserved marrow was significantly greater than for refrigerated storage, the viability and colony-forming potential of the refrigerated storage were superior or equivalent, independent of prior processing. 6 On the other hand, no clinically meaningful variation in post-transplant course and engraftment kinetics between refrigerated storage and cryopreserved stem cells was found. 5, 6, 8 Our study confirms that non-frozen stem cells are useful to support patients with NHL treated with myeloablative therapies. Sierra et al. investigated the impact of frozen and non-frozen BM on engraftment kinetics and disease outcome in 94 patients with NHL autografted with frozen marrow compared with 38 who received marrow stored at 4 or 101C. No significant differences were found in the period of time required to achieve a granulocyte count higher than 0.5 Â 10 9 /l or a platelet count higher than 20 Â 10 9 /l. In addition, both groups behaved similarly with respect to toxic death, response rate, DFS and relapse rate. 8 One potential advantage to refrigerated storage is that it may provide an opportunity for extended exposure to growth factors and/or purging agents in vitro before transplantation. 6 Storage of PBPC overnight at 41C allows pooling of consecutive-day collections resulting in decreased costs and processing time without compromising neutrophil and platelet engraftment after infusion of CD34 þ -selected progenitor cells. 9 The approximate cost of this simplified procedure was 10.8% for in-hospital procedures and for outpatient autografts, substantially lower than the figures reported from the US for autotransplants. 10 In our center, it is about 12% less costly than the cryopreserved autotransplantation. Ruiz-Arguelles and co-workers described their 10-year period experience in a private practice setting in Mexico using noncryopreserved and unmanipulated PBSC autotransplantation. The approach was feasible and results in a substantial decrease in the cost of the autologous transplantation methods 11 and this makes it suitable for developing countries.
In this study, we used the combination of cyclophosphamide, etoposide and carboplatine followed by PBSCT. It was beneficial in the treatment of relapsed or refractory lymphoma. Disease-free survival over 2 years can be achieved in some patients. The results are at least equivalent to other published regimens including TBIbased regimens. [12] [13] [14] [15] The regimen appears a particularly attractive alternative for patients who received dose-limiting radiotherapy and should be evaluated further in prospective, randomized trials. Being short term, it allows the use of non-cryopreserved stem cell transplantation.
In conclusion, this simplified approach for autografting patients, avoiding purging procedures and cryopreservation of the cells is feasible and results in a substantial decrease of the cost of autologous hematopoietic stem cell transplantation methods. On the other hand, the results of the study are encouraging insofar that the DFS and OS are comparable to other protocols of high-dose chemotherapy and PBSCT.
